<DOC>
	<DOCNO>NCT02213029</DOCNO>
	<brief_summary>This multi-cohort phase I study design ass pharmacokinetics ( PK ) pharmacodynamics ( PD ) oxytocin evaluate epelsiban ( GSK557296 ) potential reduce subendometrial contractractility induce oxytocin healthy female subject . Additionally tissues concentration epelsiban determine endometrial tissue biopsy . Data study inform identification dose epelsiban use future in-vitro fertilization ( IVF ) clinical study . Expected number subject randomize : Cohort 1- 10 subject , Cohort 2a- 10 subject epelsiban arm 25 milligram ( mg ) , 200mg , 5 placebo , Cohort 2b- 10 subject per arm dose determine , cohort 3- 6 subject . Cohorts 1 2 double blind ( sponsor unblinded ) placebo control cohort . Cohort 3 open label cohort , cohort 4 double blind ( sponsor unblinded ) placebo control cohort .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Pharmacodynamics Tissue Concentrations Epelsiban</brief_title>
	<detailed_description />
	<mesh_term>Diketopiperazines</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>For ultrasound training cohort Female volunteer childbearing potential ; negative pregnancy test determine human chorionic gonadotropin ( hCG ) test screen prior study initiation . Age 18 35 year old ( inclusive ) . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 1830 kg/meter ( ) ^2 ( inclusive ) . Normal ovarian uterine anatomy assess transvaginal ultrasonography . Capable give write informed consent , include compliance requirement restriction list consent form . Is good physical mental health determine responsible experienced physician , base medical evaluation include medical history , physical examination . For Cohorts 1 , 2A , 2B , 2C , 3 Female volunteer childbearing potential ; negative pregnancy test determine hCG test screen prior study initiation . Agrees use one contraception method 2 week prior start study minimize risk pregnancy . Female subject must agree use contraception least 48 hour pass last dose study drug . OR samesex partner , prefer usual lifestyle . Oral contraceptive ( OC ) pill naive discontinue OC least 2 month prior study entry . Age 18 35 year old . Body weight &gt; =50 kg BMI within range 1830 kg/m^2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form sign consent form ; good physical mental health determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation GlaxoSmithKline ( GSK ) Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Subjects blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit ( MI ) U/milliliter ( mL ) estradiol &lt; 40 picogram/mL ( &lt; 147 picomoles/Liter ) always exclude enrolment . base single average correct QTc value triplicate ECGs obtain brief recording period : QTc &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block . For Training Cohort Ultrasonographic evidence uterine anomaly , include limited intramural submucosal leiomyoma ( fibroid ) cyst , endometrial polyp , American Society Reproductive Medicine ( ASRM ) Class IVI uterine malformation intrauterine fluid collection . Pregnancy ( suspect diagnose ) lactation . Has prior partial total hysterectomy tubal ligation . Currently use intrauterine device ( IUD ) reason . History suspicion drug alcohol abuse . Criteria Based Upon Medical Histories For Training Cohort Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 7 drink . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Criteria Based Upon Diagnostic Assessments For Training Cohort A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol/ ; . A positive test human immune virus ( HIV ) antibody . For Cohorts 1 , 2A , 2B , 2C , 3 Female abnormal obstetric profile ( average duration &lt; 27 day &gt; 31 day ; Any contraindication oral contraception use ; Is use hormone replacement therapy ( HRT ) ; Ultrasonographic evidence ovarian dysfunction , Polycystic Ovary Syndrome ( PCOS ) ovarian anomaly dermoid hemorrhagic cyst ; Ultrasonographic evidence uterine anomaly , include limited intramural submucosal leiomyoma ( fibroid ) cyst , endometrial polyp , ASRM Class IVI uterine malformation intrauterine fluid collection . Pregnancy ( suspect diagnose ) lactation . Has prior partial total hysterectomy tubal ligation . Has prior surgical procedure cervix ( cryoablation , loop electrical excision procedure [ LEEP ] similar procedure ) . Currently use IUD reason . Potential volunteer high risk develop complication take oral contraceptive enter study accordance normal standard good clinical practice . History suspicion drug alcohol abuse . Criteria Based Upon Medical Histories For Cohorts 1 , 2 , 3 Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 7 drink . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History hypertension , use antihypertensive , systolic blood pressure &gt; =140 millimeter mercury ( mmHg ) diastolic blood pressure &gt; =90 mmHg . Criteria Based Upon Diagnostic Assessments For Cohorts 1 , 2 , 3 A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol/cotinine screen . A positive test HIV antibody . Other Criteria The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>epelsiban</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>patient report pain / discomfort</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>oxytocin infusion</keyword>
	<keyword>Uterine contraction</keyword>
</DOC>